---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-181293"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:13:25.617051+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies receives Nasdaq notice for Audit Committee non-compliance after director resignation

## Summary
- On June 13, 2023, board member Leslie Trigg resigned, reducing Audit Committee to two members.
- Nasdaq rule 5605(c)(2)(A) requires at least three members on Audit Committee.
- Company received non-compliance notice on June 26, 2023, with a cure period to regain compliance.
- Company is evaluating board committee composition and intends to cure within the applicable period.

## SEC filing metadata
- accession: 0001193125-23-181293
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312523181293/0001193125-23-181293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312523181293/d530995d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-181293
- JSON: https://secwatch.observer/filing/0001193125-23-181293.json
- Plain text: https://secwatch.observer/filing/0001193125-23-181293.txt

## Key facts
- Listing & Compliance Notices
  Adaptive Biotechnologies Corp received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605(c)(2)(A)
  source text: June 26, 2023, the Company received a notice from Nasdaq regarding non-compliance with the rule requiring three members to serve on an Audit Committee and confirming the cure period applicable to the Company. The Company is evaluating the appropriate composition of its board committees and fully intends to regain compliance with Rule 5605(c)(2)(A) within the applicable cure period. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Adaptive Biotechnol
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000119312523181293/0001193125-23-181293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.